Today's Veterinary Practice

JUL-AUG 2012

Today's Veterinary Practice provides comprehensive information to keep every small animal practitioner up to date on companion animal medicine and surgery as well as practice building and management.

Issue link: http://todaysveterinarypractice.epubxp.com/i/75883

Contents of this Issue

Navigation

Page 40 of 91

SELECTING CONTINUING EDUCATION FOR YOUR PRACTICE TEAM | TRIFEXIS™ (spinosad + milbemycin oxime) Chewable Tablets 4. Establish whether employees will be evaluated on their will- ingness to participate in CE dur- ing their annual performance ÀiÛiiÜÃ°Ê -omiÊ «À>VÌiViÃÊ ÀiµÕiÀiÊ that team members attend at least eight hours of continuing educa- tion within a 12-month period. 5. Create a career development plan for each team member out- lining the year's training plan. This plan is mutually agreed upon during the yearly evaluation. 6. Develop a system to track CE hours, such as how many CE hours are required for veterinar- ians and credentialed technicians annually and deadlines for sub- mission of these hours, since each state has different regulations regarding CE requirements. Continuing education can be a valu- able investment if you are methodical Sheila Grosdidier, RVT, PHR, is a partner/ consultant with Veterinary Management Consultation, Inc, and spe- cializes in staff training/ utilization, client service excellence, and technical proficiency within veterinary practices. She is also an editorial advisory board member for Today's Veterinary Practice. Ms. Grosdidier conducts extensive on-site consultations and has developed a seminar series directed toward taking practices to their next level. She has authored numerous book chapters and journal articles, lec- tures nationally and internationally, and has been named Speaker of the Year by the NAVC Conference and International/Australia Veterinary Nurses Association. Prior to her current position, she was a senior veterinary educator with Hill's Pet Nutrition, Inc, and also a director of information technologies and certified systems administrator in both Unix and Microsoft operating environ- ments. Ms. Grosdidier received her BS in human behavioral science from about your approach. It will boost your team's morale, give them the opportu- nity to increase their knowledge base and experience, and ultimately provide the best care for the patients in your practice. ■ CE = continuing education Resources 1. Allen DG. Retaining Talent–Society of Human Resources Managers Report, 2008, shrm. org/about/foundation/research/Documents/ Retaining%20Talent-%20Final.pdf 2. Whitehead M. Businesses Invested in Employee Training During Downturn. Birkhead Associates, 2008. 3. Cosh A, Hughes A, Bullock A, Potton M. The relationship between training and business performance. Research Report RR454. University of Cambridge, 2003, p 4. 4. 2010 State of the Industry Report. American Society for Training & Development (ASTD), 2010. 5. Benchmarks 2011: A Study of Well Managed Practices. Lenexa, KS: Veterinary Economics, industrymatter.com. New York Institute of Technology and her AA in veterinary technology from Maple Woods College in Kansas City, Missouri. She has also completed postgraduate work in psychology and adult learning. Monica Dixon Perry, CVPM, is a consultant and speaker for Veterinary Management Consultation, Inc, present- ing the seminar Principles of Veterinary Practice Management throughout the U.S. She has lectured at national and international veterinary conferences as well as veterinary schools and written numerous veteri- nary management articles. In addition to lecturing, Ms. Perry consults with practices on-site, assisting owners, managers and administrators, and health care team members as a coach and mentor. Prior to her current position, she managed a full-service small animal practice in Raleigh, North Carolina, for 11 years. Ms. Perry received her BS in biology from University of North Carolina and is a Certified Veterinary Practice Manager. Before using TRIFEXIS chewable tablets, please consult the product insert, a summary of which follows: Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Indications: TRIFEXIS is indicated for the prevention of heartworm disease ( ¿ÈÅŰ·ȿ· ¿ÃÿʿÉƻƔ ÆȻ̻ÄÊ¿ÅÄ ·Äº ÊÈ»·ÊûÄÊ Å¼ Ų»· ¿Ä¼»ÉÊ·Ê¿ÅÄÉ ƺ Ê»ÄŹ»Æ¾·Â¿º»É ¼»Â¿É), and the treatment and control of adult hookworm ( ĹÏÂÅÉÊÅ÷ ¹·Ä¿ÄËÃ), adult roundworm ( ÅÎŹ·È· ¹·Ä¿É and Åηɹ·È¿É »ÅÄ¿Ä·) and adult whipworm ( È¿¹¾ËÈ¿É ÌËÂÆ¿É) infections in dogs and puppies 8 weeks of age or older and 5 pounds of body weight or greater. Contraindications: There are no known contraindications to the use of TRIFEXIS Chewable Tablets. Warnings: Not for human use. Keep this and all drugs out of the reach of children. Serious adverse reactions have been reported following concomitant extra-label use of ivermectin with spinosad alone, one of the components of TRIFEXIS Chewable Tablets (see ADVERSE REACTIONS). Precautions: Treatment with fewer than 3 monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention (see EFFECTIVENESS). Prior to administration of TRIFEXIS, dogs should be tested for existing heartworm infection. At the discretion of the veterinarian, infected dogs should be treated with an adulticide to remove adult ¾»·ÈÊÍÅÈÃÉƔ ¿É ÄÅÊ »Ů»¹Ê¿Ì» ·½·¿ÄÉÊ ·ºËÂÊ Ɣ ¿ÃÿʿÉ. ¾¿Â» ʾ» ÄËø»È ż ¹¿È¹Ë·ʿĽ ÿ¹ÈÅŰ·ȿ·» Ã·Ï º»¹È»·É» ¼ÅÂÂÅͿĽ ÊÈ»·ÊûÄÊƑ ¿É ÄÅÊ ¿Äº¿¹·Ê»º ¼ÅÈ Ã¿¹ÈÅŰ·ȿ·» clearance. Mild, transient hypersensitivity reactions manifested as labored respiration, vomiting, salivation and lethargy, have been noted in some dogs treated with milbemycin oxime carrying · ¾¿½¾ ÄËø»È ż ¹¿È¹Ë·ʿĽ ÿ¹ÈÅŰ·ȿ·»Ɣ ¾»É» È»·¹Ê¿ÅÄÉ ·È» presumably caused by release of protein from dead or dying ÿ¹ÈÅŰ·ȿ·»Ɣ Use with caution in breeding females. The safe use of TRIFEXIS in breeding males has not been evaluated. Use with caution in dogs with pre-existing epilepsy. Puppies less than 14 weeks of age may experience a higher rate of vomiting. Adverse Reactions: Ä · Í»ÂÂƖ¹ÅÄÊÈÅ»º Ű»Âº ÉÊ˺ÏƑ ;¿¹¾ ¿Ä¹Â˺»º · ÊÅʷ ż 352 dogs (176 treated with TRIFEXIS chewable tablets and 176 treated with an active control), no serious adverse reactions were attributed to administration of TRIFEXIS chewable tablets. All reactions were regarded as mild. Reactions that occurred at an incidence >2% (average monthly rate) within any of the 6 months of observation are presented in the following table: Average Monthly Rate (%) of Dogs With Adverse Reactions Adverse Reaction Vomiting Pruritus Lethargy Diarrhea a n=176 dogs Ä Ê¾» TRIFEXIS Chewable Tabletsa 6.13 4.00 2.63 2.25 Ű»Âº ÉÊ˺ÏƑ ÅÄ» ºÅ½ ·ºÃ¿Ä¿ÉʻȻº 3.08 4.91 1.54 1.54 »Îƻȿ»Ä¹»º a single mild seizure 2½ hours after receiving the second monthly dose. The dog remained enrolled and received four additional monthly doses after the event and completed the study without further incident. Following concomitant extra-label use of ivermectin with spinosad alone, a component of TRIFEXIS, some dogs have experienced the following clinical signs: ÊȻø¿ĽƭÊͿʹ¾¿Ä½Ƒ ɷ¿̷ʿÅÄƭºÈÅÅ¿ĽƑ É»¿ÐËÈ»ÉƑ ·Ê·Î¿·Ƒ ÃϺȿ·É¿ÉƑ ¸Â¿ÄºÄ»ÉÉ ·Äº º¿ÉÅÈ¿»ÄÊ·Ê¿ÅÄ. Spinosad alone has been shown to be safe when administered concurrently with heartworm preventatives at label directions. Ä ·Äº ËÈÅÆ»·Ä Ű»Âº ÉÊ˺¿»ÉƑ ÄÅ ºÅ½É »Îƻȿ»Ä¹»º É»¿ÐËÈ»É when dosed with spinosad alone at the therapeutic dose range of 13.5-27.3 mg/lb (30-60 mg/kg), including 4 dogs with pre-existing epilepsy. Four epileptic dogs that received higher than the maximum recommended dose of 27.3 mg/lb (60 mg/kg) experienced at least one seizure within the week following the É»¹Åĺ ºÅÉ» ż ÉÆ¿ÄÅÉ·ºƑ ¸ËÊ ÄÅ É»¿ÐËÈ»É ¼ÅÂÂÅͿĽ ʾ» ŰÈÉÊ ·Äº ʾ¿Èº ºÅÉ»ÉƔ ¾» ¹·ËÉ» ż ʾ» É»¿ÐËÈ»É Å¸É»ÈÌ»º ¿Ä ʾ» Ű»Âº ÉÊ˺¿»É could not be determined. For technical assistance or to report an adverse drug reaction, call 1-888-545-5973. Additional information can be found at www.TRIFEXIS.com. Ů»¹Ê¿Ì»Ä»ÉÉƓ »·ÈÊÍÅÈà Ȼ̻ÄÊ¿ÅÄƓ In a well-controlled laboratory study, TRIFEXIS was 100% »Ů»¹Ê¿Ì» ·½·¿ÄÉÊ ¿ÄºË¹»º ¾»·ÈÊÍÅÈà ¿Ä¼»¹Ê¿ÅÄÉ Í¾»Ä ·ºÃ¿Ä¿ÉʻȻº for 3 consecutive monthly doses. Two consecutive monthly doses º¿º ÄÅÊ ÆÈÅÌ¿º» ʸʷʷ̈ »Ů»¹Ê¿Ì»Ä»ÉÉ ·½·¿ÄÉÊ ¾»·ÈÊÍÅÈà ¿Ä¼»¹Ê¿ÅÄƔ In another well-controlled laboratory study, a single dose of Í·É ʸʷʷ̈ »Ů»¹Ê¿Ì» ·½·¿ÄÉÊ ¿ÄºË¹»º ¾»·ÈÊÍÅÈà ¿Ä¼»¹Ê¿ÅÄÉƔ Ä · Í»ÂÂƖ¹ÅÄÊÈÅ»º É¿ÎƖÃÅÄʾ Ű»Âº ÉÊËºÏ ¹Åĺ˹ʻº with TRIFEXIS, no dogs were positive for heartworm infection as determined by heartworm antigen testing performed at the end of the study and again three months later. »· È»·ÊûÄÊ ·Äº Ȼ̻ÄÊ¿ÅÄƓ In a well-controlled laboratory study, TRIFEXIS demonstrated ʸʷʷ̈ »Ů»¹Ê¿Ì»Ä»ÉÉ ÅÄ Ê¾» ŰÈÉÊ º·Ï ¼ÅÂÂÅͿĽ ÊÈ»·ÊûÄÊ ·Äº ʸʷʷ̈ »Ů»¹Ê¿Ì»Ä»ÉÉ ÅÄ ·Ï ˝ʷƔ Ä · Í»ÂÂƖ¹ÅÄÊÈÅ»º ·¸ÅÈ·ÊÅÈÏ ÉÊ˺ÏƑ ÉÆ¿ÄÅÉ·ºƑ · ¹ÅÃÆÅÄ»ÄÊ Å¼ Ƒ ¸»½·Ä ÊÅ Á¿Â Ų»·É 30 minutes after administration and demonstrated 100% »Ů»¹Ê¿Ì»Ä»ÉÉ Í¿Ê¾¿Ä ʻ ¾ÅËÈÉƔ Ä Ű»Âº ÉÊ˺¿»É ¹Åĺ˹ʻº ¿Ä ¾ÅËÉ»¾ÅÂºÉ Í¿Ê¾ »Î¿ÉʿĽ Ų»· ¿Ä¼»ÉÊ·Ê¿ÅÄÉ Å¼ Ì·ÈϿĽ ɻ̻ȿÊÏƑ Ų»· reductions of 98.0% to 99.8% were observed over the course of ˝ ÃÅÄʾÂÏ ÊÈ»·ÊûÄÊÉ Í¿Ê¾ ÉÆ¿ÄÅÉ·º ·ÂÅÄ»Ɣ È»·ÊûÄÊ ·Äº ÅÄÊÈÅ ż ÄÊ»ÉÊ¿Ä·Â »Ã·Êź» ļ»¹Ê¿ÅÄÉƓ Ä Í»ÂÂƖ¹ÅÄÊÈÅ»º ·¸ÅÈ·ÊÅÈÏ ÉÊ˺¿»ÉƑ NADA #141-321, Approved by the FDA Manufactured for Elanco Animal Health A Division of Eli Lilly & Co. Lilly Corporate Center, Indianapolis, IN 46285 Trifexis™ is a trademark of Eli Lilly and Company PA9945DEAMX (V01-12-2010) Active Control Tabletsa Á¿ÂÂÉ Ų»·É ·Äº ¿É ¿Äº¿¹·Ê»º ¼ÅÈ Ê¾» Å½É Í¿Ê¾ É¿½ÄÉ Å¼ Ų»· allergy dermatitis showed improvement in erythema, papules, scaling, alopecia, dermatitis/pyodermatitis and pruritus as a direct È»ÉËÂÊ Å¼ »Â¿Ã¿Ä·Ê¿Ä½ ʾ» Ų»·ÉƔ Í·É ̟ ˀʷ̈ »Ů»¹Ê¿Ì» ¿Ä È»ÃÅ̿Ľ Ä·ÊËÈ·ÂÂÏ ·Äº »ÎƻȿûÄÊ·ÂÂÏ ¿ÄºË¹»º ·ºËÂÊ roundworm, whipworm and hookworm infections. July/August 2012 Today's Veterinary Practice 39

Articles in this issue

Links on this page

Archives of this issue

view archives of Today's Veterinary Practice - JUL-AUG 2012